Potential new treatment for advanced solid tumours and lymphomas

University of the Sunshine Coast has begun a clinical trial evaluating a phase 1 investigational drug, ONM-501 alone and in combination with cemiplimab in patients with advanced solid tumours and lymphomas. The ONM-501 is given intratumorally and helps generate a stronger and more prolonged innate immune response that more effectively translates to a robust adaptive immune response. We are seeking applicants aged 18 years or older with advanced or recurrent solid tumours and lymphomas that have not responded to other treatments to participate in the study.

The trial will be overseen by Principal Investigator Dr Hong Shue at Sunshine Coast Haematology and Oncology Clinic (SCHOC) in Buderim on the Sunshine Coast and supported by our experienced clinical trials staff.

We are seeking applications from people who:

• are aged 18 years or older
• have solid tumours or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or recurrent and progressing since last antitumour therapy
• have at least one tumour that can be assessed
• have not had any major surgery four weeks prior to the first dose
• can attend regular visits at Sunshine Coast Haematology and Oncology Clinic in Buderim.

If you have patients who fit the criteria and who would be suitable for the trial, we would appreciate your consideration of their participation.

Participation will be free of charge and private health insurance is not required.

Please do not hesitate to contact us on 07 5409 8640 for further information.